

Amendment to the claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1-5. (Cancelled).

6. (Currently amended) A compound for vaccination of an animal comprising (i) a moiety selected from any of HIV gp120, the LAM protein of *Mycobacterium tuberculosis* or a glycoprotein of Ebola virus, or parts thereof, and (ii) an antigen.

7. (Currently amended) The compound according to Claim 6, + wherein the antigen is a polypeptide.

8. (Currently amended) The compound according to Claim 6, + wherein the antigen is a molecule associated with a disease of the animal or part or variant of such a molecule.

9. (Currently amended) The compound according to Claim 6, 8 wherein the antigen comprises two or more molecules associated with a disease of the animal or parts or variants of such molecules.

10. (Currently amended) The compound according to Claim 6, 8 wherein the antigen is an antigenic component of a pathogen or a tumour or an antigenic part or variant of such a component.

11. (original) The compound according to Claim 10, wherein the pathogen is any of a bacterium, virus, fungus, protozoa or helminth.

12. (Currently amended) The compound according to Claim 6, + wherein the antigen is an antigenic component of a pathogen selected from pathogens associated with OIE list A diseases, or a part or variant of such a component.

13. (Currently amended) The compound according to Claim 6, ~~+~~ wherein the HIV gp120 moiety and the antigen are covalently linked.

14. (Currently amended) The compound according to Claim 6, ~~+~~ wherein the HIV gp120 moiety which selectively binds, and the antigen each comprise a polypeptide and both are present in the same polypeptide chain.

15-17. (Cancelled).

18. (Currently amended) A vaccine comprising the compound according to Claim 6 ~~+~~ ~~or the nucleic acid molecule according to Claim 15.~~

19. (Previously presented) The vaccine according to Claim 18 further comprising an adjuvant.

20. (Cancelled).

21. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 6 ~~+~~ ~~or a nucleic acid molecule according to Claim 15~~ and a pharmaceutically acceptable carrier.

22. (currently amended) A method of immunizing ~~immunising~~ an animal against a disease, the method comprising the to step of administering to the animal a compound according to Claim 6 ~~+~~ ~~or a nucleic acid molecule according to Claim 15.~~

23. (currently amended) A method of combating a disease in an animal, the method comprising the step of administering to the animal a compound according to Claim 6 ~~+~~ ~~or a nucleic acid molecule according to Claim 15.~~

24. (original) The method according to any one of Claims 22 or 23 wherein the disease is one caused by a pathogen.

25. (original) The method according to Claim 24 wherein the pathogen is any of a bacterium, virus, fungus, protozoa or helminth.

26. (original) The method according to Claim 25 wherein the pathogen is one associated with OIE List A diseases.

27. (original) The method according to any one of Claim 22 or 23 wherein the animal is a mammal.

28. (previously presented) The method according to Claim 22 wherein the animal is a companion animal or farm animal.

29. (previously presented) The method according to Claim 28 wherein the animal is a cow, sheep, horse, pig, goat, dog, cat or rabbit.

30-37. (Cancelled).

38. (Currently amended) A method of making a the compound of ~~according to~~ Claim ~~4 or 6~~, the method comprising linking the HIV gp120, or a part thereof, ~~said moiety~~ with ~~and~~ the said antigen.

39-44. (cancelled).

45. (Currently amended) A method of determining whether an animal has been administered a the compound of ~~according to~~ Claim 6 ~~4~~, the method comprising determining whether the animal has or had an immune response to HIV gp120 ~~said moiety which selectively binds to a dendritic cell~~.

46. (Currently amended) ~~The A method of according to Claim 45~~ further comprising the ~~further step of~~ determining whether the animal has or had an immune response to the antigen ~~present in said compound.~~

47. (Currently amended) A kit of ~~parts~~ comprising

(i) a ~~the~~ compound of according to Claim 6; ~~1 or a nueleic acid molecule according to Claim 15 and~~

(ii) ~~means~~ part for detecting an immune response to HIV gp120; ~~or the moiety present in said compound which selectively binds to a dendritic cell, and/or~~

(iii) ~~means~~ part for detecting an immune response to the antigen ~~present in said compound.~~

48. (Currently amended) ~~The A kit of parts according to Claim 47,~~ wherein ~~if present part~~ (ii) comprises all, or a portion of, ~~said moiety which~~ HIV gp120 that binds to an antibody raised against said all or a portion of HIV gp120, ~~wherein moiety and~~ part (iii) comprises all, or a portion, of said antigen ~~so which~~ that binds to an antibody raised against said antigen.

49. (Cancelled).

50. (Currently amended) ~~The A kit of parts according to Claim 47,~~ wherein (ii) and (iii) each comprises ~~the means for detecting an immune response is~~ an ELISA.

51. (Cancelled).